Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled dose-ranging study of BI 1291583 in bronchiectasis
MOH_2022-08-09_011963Phase 2Not yet recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of verducatib in bronchiectasis (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Time to first pulmonary exacerbation up to week 48. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
verducatib
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on MOH_2022-08-09_011963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-08-09_011963.